3.4.21.B45: kallikrein 14

synthetic inhibitor

693084

alpha1-Aantichymotrypsin

forms covalent complex with hK14

668566

alpha1-antitrypsin

forms covalent complex with hK14

668566

HAI-1A

no inhibition of KLK14 up to equimolar concentrations (5 nm) of enzyme and inhibitor. As the reaction shifts to containing excess inhibitor, KLK14 is mildly inhibited, with inhibition of 35% obtained when HAI-1A is present at 10fold excess over protease

752884

HAI-1B

no inhibition of KLK14 up to equimolar concentrations (5 nm) of enzyme and inhibitor. As the reaction shifts to containing excess inhibitor, KLK14 is mildly inhibited, with inhibition of 26% obtained when HAI-1B is present at 10fold excess over protease

752884

lympho-epithelial Kazal type inhibitor fragment D5

lympho-epithelial Kazal type inhibitor fragment D8-D11

lympho-epithelial Kazal type inhibitor fragment D9-D15

Spink6

i.e. serine protease inhibitor Kazal type 6. Selective inhibitor of kallikreins in the skin. Spink6 possesses only one typical Kazal domain. Its mRNA is expressed at low levels in several tissues and is induced during keratinocyte differentiation. Spink6 is expressed in the stratum granulosum of human skin at various anatomical localisations and in the skin appendages, including sebaceous glands and sweat glands. Spink6 expression is decreased in lesions of atopic dermatitis. Recombinant SPINK6 is inhibitory for KLK5, KLK7 and KLK14

709135

vaspin

vaspin represents a multispecific serpin targeting the kallikrein proteases KLK7 and KLK14

752891

Zn2+

semenogelins are able to reverse KLK14 inhibition by Zn2+

693084

additional information

not inhibited by lympho-epithelial Kazal type inhibitor fragments D1 and D6